Lilly Delivers Strong Third-Quart...( for the first-line treatment of a...),Health

the first-line treatment of advanced non-small cell lung cancer.

-- In September, the U.S. Food and Drug Administration approved a new,

pre-filled insulin pen, KwikPen(TM), which will be available with any

of the Humalog formulations. Launch is expected in early 2008.

-- In October, the United States Supreme Court denied the petitions for

certiorari that were filed by Teva Pharmaceuticals and Dr. Reddy's

Laboratories regarding their challenges to the validity of Lilly's U.S.

Zyprexa patent.

-- In October, as a part of ongoing discussions with the U.S. Food and

Drug Administration, the company updated the Zyprexa (olanzapine) and

Symbyax (olanzapine and fluoxetine HCl) U.S. product labels.

Specifically, the changes include new warnings for weight gain and

hyperlipidemia (elevation of triglycerides and cholesterol) and updated

information in the warning for hyperglycemia (elevated blood sugar).

The label also states that while relative risk estimates are

inconsistent, the association between atypical antipsychotics and

increases in glucose levels appears to fall on a continuum and

olanzapine appears to have a greater association than some other

atypical antipsychotics.

"Lilly continued to deliver excellent financial results to our shareholders in the third quarter, and we remain on pace for a very solid year," commented Sidney Taurel, chairman and chief executive officer. "Our ongoing focus on volume-based revenue growth and cost containment again allowed us to leverage double-digit sales growth into robust earnings per share results for the quarter on a pro forma adjusted basis."

Third-Quarter Reported Results

Worldwide reported sales for the quarter were $4.587 billion, an increase of 19 percent compared with the third quarter of 2006. Worldwide sales volume increased 14 percent,
'/>"/>